Overview

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2011-01-01

Target enrollment:

Participant gender:

Summary

The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects. The purpose of the Phase II portion is to find out how safe the study drug is when taken at the highest dose in a larger group of subjects.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

PharmaBio Development Inc.

Treatments:

Bevacizumab
Calcium
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin